Intuitive Surgical, Inc. ISRG
Composite 59/100; the shares have moved about 40% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 21/100 — a strong mark against it.
Balance-sheet strength ranks 94/100 — a strong point in its favour. Growth ranks 77/100 — a strong point in its favour. Quality ranks 72/100 — a moderate point in its favour.
Momentum ranks 21/100 — a strong mark against it. Valuation ranks 24/100 — a strong mark against it.
What the company does Intuitive Surgical designs and sells robotic-assisted surgical systems, including the da Vinci Surgical System and Ion endoluminal system, enabling minimally invasive procedures. Its offerings span hardware, instrumentation, digital capabilities, and customer support to hospitals globally.
Key financials The company reports strong profitability with gross margins of 66.7%, operating margins of 33.6%, and net margins of 28.4%. ROE stands at 17.4%, ROA at 10.5%, and ROCE at 19.7%. Revenue and EPS growth are both positive at 20.5% and 22.8%, respectively.
Stock health Momentum is weak, with 3-month, 6-month, and 12-month declines of -13.87%, -24.85%, and -21.16%, respectively. The stock is -37.27% below its 52-week high, and RSI(14) is 47.60, indicating neutral momentum.
Price vs fair value The stock trades at a discount of 26.00% versus the analyst mean target of 477.25. - Operating margin expansion continues despite stock decline (Trefis) - Mixed analyst sentiment on Wall Street (Barchart) - Compared unfavorably to peers with consistent growth (Insider Monkey) - Manufacturing expansion in Asia Pacific supports long-term positioning (Zacks) - Year-to-date decline described as worst since 2008 (Motley Fool) - Software strategy gaining attention alongside core robotic systems (Zacks)
Looking forward Forward P/E of 36.50 and PEG of 1.39 suggest high expectations embedded in the valuation. The company’s strong quality and growth scores (72.2 and 78.7) contrast with weak momentum and valuation percentiles (20.2 and 20.8).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.